Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology

Search Medical Condition
Please enter condition
Please choose location

Memory Problems Clinical Trials

A listing of Memory Problems medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (38) clinical trials

DAYBREAK-ALZ — the study will last 8 weeks to see if you qualify, plus 3 years of treatment, then 4 weeks of follow-up. The study drug is a tablet, to be taken once a day. The tablet will contain either a lower dose of the study drug, a higher dose ...

Phase

For some people, dementia and Alzheimer’s disease (AD) can make them feel restless or upset. The ITI-007-201 Agitation Study is looking at an investigational medication to see if it is safe and works well to help reduce how often people with dementia, including AD feel upset or anxious. If you ...

Phase N/A

Study is looking at the efficacy and safety of an investigational medication in people experiencing symptoms of Early Alzheimer's disease, such as problems with memory or thinking clearly. The study will last approximately 4 years in total, and participants will be required to attend study center visits once a month ...

Phase N/A

Northern California Research is enrolling participants for a Mild Dementia/Alzheimer's Disease study. The purpose of this study is to see if daily doses of a study medication will improve the symptoms of mild dementia due to Alzheimer's disease. This study medication has been designed to change the cortisol levels in ...

Phase

Study Description: The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype. ...

Phase

The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer's dementia. May be compensated for time and ...

Phase

The purpose of this study is to evaluate whether the investigational medication, JNJ-54861911, slows cognitive decline compared with placebo (inactive treatment) in individuals with generally normal memory and thinking ability but who are at risk for developing Alzheimer's dementia.  Study qualification and whether or not a potential study participant is ...

Phase

Dietary Flavanols and Dentate Gyrus Function

In this double blinded trial, the participants, age 50-75 years, will be randomized to receive 0, 225, 400, or 650 mg daily for 12 weeks and will be tested before and after the intervention. Cognitive testing will be conducted prior to randomization, and at weeks 4, 12, and 20 of ...

Phase N/A